Literature DB >> 17250661

Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC.

A Stella1, N C Surdo, P Lastella, D Barana, C Oliani, M G Tibiletti, A Viel, C Natale, A Piepoli, G Marra, G Guanti.   

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) is caused by inactivating mutations of DNA mismatch repair genes. Large genomic rearrangements in these genes have been increasingly recognized as important causes of HNPCC. Using multiplex ligation-dependent probe amplification, we identified three MSH2 deletions in Italian patients with HNPCC (proband A: exons 1-3, proband M: exon 8, and proband C: exons 1-6). Deletion breakpoint sequencing allowed us to develop rapid polymerase chain reaction-based mutation screening, which confirmed the presence of the deletions in affected and asymptomatic individuals of families A, C, and M. While the exon 8 and exon 1-3 deletions appear to be novel, the MSH2 1-6 deletion found in family C is identical to the one recently documented in two branches of another unrelated Italian family (family V+Va). Haplotype analysis showed that the kindreds C and V+Va (both from northeastern Italy, both displaying clinical features of the Muir-Torre syndrome) shared a seven-locus haplotype, indicating that the MSH2 1-6 deletion is probably a founder mutation. Families A, C, M, and V+Va all showed progressively earlier cancer-onset ages in successive generations. Analysis of 23 affected parent-child pairs in the four kindreds showed median anticipation of 12 years in offsprings' onset of cancer (p = 0.0001). No birth cohort effect was found. This is the first significant evidence of anticipation effects in HNPCC families carrying MSH2 deletions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17250661     DOI: 10.1111/j.1399-0004.2007.00745.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  23 in total

1.  A unique MSH2 exon 8 deletion accounts for a major portion of all mismatch repair gene mutations in Lynch syndrome families of Sardinian origin.

Authors:  Iolanda Borelli; Marco A Barberis; Francesca Spina; Guido C Casalis Cavalchini; Caterina Vivanet; Luisa Balestrino; Monica Micheletti; Anna Allavena; Paola Sala; Carlo Carcassi; Barbara Pasini
Journal:  Eur J Hum Genet       Date:  2012-07-11       Impact factor: 4.246

2.  Identification and surveillance of 19 Lynch syndrome families in southern Italy: report of six novel germline mutations and a common founder mutation.

Authors:  Patrizia Lastella; Margherita Patruno; Giovanna Forte; Alba Montanaro; Carmela Di Gregorio; Carlo Sabbà; Patrizia Suppressa; Adalgisa Piepoli; Anna Panza; Angelo Andriulli; Nicoletta Resta; Alessandro Stella
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

Review 3.  A review of statistical methods for testing genetic anticipation: looking for an answer in Lynch syndrome.

Authors:  Philip S Boonstra; Stephen B Gruber; Victoria M Raymond; Shu-Chen Huang; Susanne Timshel; Mef Nilbert; Bhramar Mukherjee
Journal:  Genet Epidemiol       Date:  2010-11       Impact factor: 2.135

4.  Multivariate analysis of MLH1 c.1664T>C (p.Leu555Pro) mismatch repair gene variant demonstrates its pathogenicity.

Authors:  M P Farrell; D J Hughes; M Drost; A J Wallace; R J Cummins; T A Fletcher; M A Meany; E W Kay; N de Wind; D G Power; E J Andrews; A J Green; D J Gallagher
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

5.  Lynch Syndrome in high risk Ashkenazi Jews in Israel.

Authors:  Yael Goldberg; Inbal Kedar; Revital Kariiv; Naama Halpern; Morasha Plesser; Ayala Hubert; Luna Kaduri; Michal Sagi; Israela Lerer; Dvorah Abeliovich; Tamar Hamburger; Aviram Nissan; Hanoch Goldshmidt; Irit Solar; Ravit Geva; Hana Strul; Guy Rosner; Hagit Baris; Zohar Levi; Tamar Peretz
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

6.  Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study.

Authors:  David C Kochan; Erin Winkler; Noralane Lindor; Gabriel Q Shaibi; Janet Olson; Pedro J Caraballo; Robert Freimuth; Joel E Pacyna; Carmen Radecki Breitkopf; Richard R Sharp; Iftikhar J Kullo
Journal:  NPJ Genom Med       Date:  2020-05-04       Impact factor: 8.617

7.  Fertility and apparent genetic anticipation in Lynch syndrome.

Authors:  Douglas Stupart; Aung Ko Win; Mark Jenkins; Ingrid M Winship; Paul Goldberg; Rajkumar Ramesar
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

8.  A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.

Authors:  Iolanda Borelli; Guido C Casalis Cavalchini; Serena Del Peschio; Monica Micheletti; Tiziana Venesio; Ivana Sarotto; Anna Allavena; Luisa Delsedime; Marco A Barberis; Giorgia Mandrile; Paola Berchialla; Paola Ogliara; Cecilia Bracco; Barbara Pasini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

9.  Copy number variations and cancer.

Authors:  Adam Shlien; David Malkin
Journal:  Genome Med       Date:  2009-06-16       Impact factor: 11.117

10.  Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.

Authors:  Katarina Zavodna; Tomas Krivulcik; Maria Gerykova Bujalkova; Tomas Slamka; David Martinicky; Denisa Ilencikova; Zdena Bartosova
Journal:  BMC Cancer       Date:  2009-11-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.